Cargando…
Glycosylation engineering of therapeutic IgG antibodies: challenges for the safety, functionality and efficacy
Glycosylation of the Fc region of IgG has a profound impact on the safety and clinical efficacy of therapeutic antibodies. While the biantennary complex-type oligosaccharide attached to Asn297 of the Fc is essential for antibody effector functions, fucose and outer-arm sugars attached to the core he...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Higher Education Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777974/ https://www.ncbi.nlm.nih.gov/pubmed/28597152 http://dx.doi.org/10.1007/s13238-017-0433-3 |
_version_ | 1783294264005885952 |
---|---|
author | Mimura, Yusuke Katoh, Toshihiko Saldova, Radka O’Flaherty, Roisin Izumi, Tomonori Mimura-Kimura, Yuka Utsunomiya, Toshiaki Mizukami, Yoichi Yamamoto, Kenji Matsumoto, Tsuneo Rudd, Pauline M. |
author_facet | Mimura, Yusuke Katoh, Toshihiko Saldova, Radka O’Flaherty, Roisin Izumi, Tomonori Mimura-Kimura, Yuka Utsunomiya, Toshiaki Mizukami, Yoichi Yamamoto, Kenji Matsumoto, Tsuneo Rudd, Pauline M. |
author_sort | Mimura, Yusuke |
collection | PubMed |
description | Glycosylation of the Fc region of IgG has a profound impact on the safety and clinical efficacy of therapeutic antibodies. While the biantennary complex-type oligosaccharide attached to Asn297 of the Fc is essential for antibody effector functions, fucose and outer-arm sugars attached to the core heptasaccharide that generate structural heterogeneity (glycoforms) exhibit unique biological activities. Hence, efficient and quantitative glycan analysis techniques have been increasingly important for the development and quality control of therapeutic antibodies, and glycan profiles of the Fc are recognized as critical quality attributes. In the past decade our understanding of the influence of glycosylation on the structure/function of IgG-Fc has grown rapidly through X-ray crystallographic and nuclear magnetic resonance studies, which provides possibilities for the design of novel antibody therapeutics. Furthermore, the chemoenzymatic glycoengineering approach using endoglycosidase-based glycosynthases may facilitate the development of homogeneous IgG glycoforms with desirable functionality as next-generation therapeutic antibodies. Thus, the Fc glycans are fertile ground for the improvement of the safety, functionality, and efficacy of therapeutic IgG antibodies in the era of precision medicine. |
format | Online Article Text |
id | pubmed-5777974 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Higher Education Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-57779742018-02-01 Glycosylation engineering of therapeutic IgG antibodies: challenges for the safety, functionality and efficacy Mimura, Yusuke Katoh, Toshihiko Saldova, Radka O’Flaherty, Roisin Izumi, Tomonori Mimura-Kimura, Yuka Utsunomiya, Toshiaki Mizukami, Yoichi Yamamoto, Kenji Matsumoto, Tsuneo Rudd, Pauline M. Protein Cell Review Glycosylation of the Fc region of IgG has a profound impact on the safety and clinical efficacy of therapeutic antibodies. While the biantennary complex-type oligosaccharide attached to Asn297 of the Fc is essential for antibody effector functions, fucose and outer-arm sugars attached to the core heptasaccharide that generate structural heterogeneity (glycoforms) exhibit unique biological activities. Hence, efficient and quantitative glycan analysis techniques have been increasingly important for the development and quality control of therapeutic antibodies, and glycan profiles of the Fc are recognized as critical quality attributes. In the past decade our understanding of the influence of glycosylation on the structure/function of IgG-Fc has grown rapidly through X-ray crystallographic and nuclear magnetic resonance studies, which provides possibilities for the design of novel antibody therapeutics. Furthermore, the chemoenzymatic glycoengineering approach using endoglycosidase-based glycosynthases may facilitate the development of homogeneous IgG glycoforms with desirable functionality as next-generation therapeutic antibodies. Thus, the Fc glycans are fertile ground for the improvement of the safety, functionality, and efficacy of therapeutic IgG antibodies in the era of precision medicine. Higher Education Press 2017-06-08 2018-01 /pmc/articles/PMC5777974/ /pubmed/28597152 http://dx.doi.org/10.1007/s13238-017-0433-3 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Review Mimura, Yusuke Katoh, Toshihiko Saldova, Radka O’Flaherty, Roisin Izumi, Tomonori Mimura-Kimura, Yuka Utsunomiya, Toshiaki Mizukami, Yoichi Yamamoto, Kenji Matsumoto, Tsuneo Rudd, Pauline M. Glycosylation engineering of therapeutic IgG antibodies: challenges for the safety, functionality and efficacy |
title | Glycosylation engineering of therapeutic IgG antibodies: challenges for the safety, functionality and efficacy |
title_full | Glycosylation engineering of therapeutic IgG antibodies: challenges for the safety, functionality and efficacy |
title_fullStr | Glycosylation engineering of therapeutic IgG antibodies: challenges for the safety, functionality and efficacy |
title_full_unstemmed | Glycosylation engineering of therapeutic IgG antibodies: challenges for the safety, functionality and efficacy |
title_short | Glycosylation engineering of therapeutic IgG antibodies: challenges for the safety, functionality and efficacy |
title_sort | glycosylation engineering of therapeutic igg antibodies: challenges for the safety, functionality and efficacy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777974/ https://www.ncbi.nlm.nih.gov/pubmed/28597152 http://dx.doi.org/10.1007/s13238-017-0433-3 |
work_keys_str_mv | AT mimurayusuke glycosylationengineeringoftherapeuticiggantibodieschallengesforthesafetyfunctionalityandefficacy AT katohtoshihiko glycosylationengineeringoftherapeuticiggantibodieschallengesforthesafetyfunctionalityandefficacy AT saldovaradka glycosylationengineeringoftherapeuticiggantibodieschallengesforthesafetyfunctionalityandefficacy AT oflahertyroisin glycosylationengineeringoftherapeuticiggantibodieschallengesforthesafetyfunctionalityandefficacy AT izumitomonori glycosylationengineeringoftherapeuticiggantibodieschallengesforthesafetyfunctionalityandefficacy AT mimurakimurayuka glycosylationengineeringoftherapeuticiggantibodieschallengesforthesafetyfunctionalityandefficacy AT utsunomiyatoshiaki glycosylationengineeringoftherapeuticiggantibodieschallengesforthesafetyfunctionalityandefficacy AT mizukamiyoichi glycosylationengineeringoftherapeuticiggantibodieschallengesforthesafetyfunctionalityandefficacy AT yamamotokenji glycosylationengineeringoftherapeuticiggantibodieschallengesforthesafetyfunctionalityandefficacy AT matsumototsuneo glycosylationengineeringoftherapeuticiggantibodieschallengesforthesafetyfunctionalityandefficacy AT ruddpaulinem glycosylationengineeringoftherapeuticiggantibodieschallengesforthesafetyfunctionalityandefficacy |